Enclosed

Poly Medicure Limited )IPOLYMED Regd. Office: 232 B, 3rd Floor; Okhla Industrial Estate, Phase-Ill, New Delhi -110 020 (INDIA) T: +91-11-33550700, 47317000 E: info@polymedicure.com W. polymedicure.com CIN:L40300DL1995PLC066923 Date: 14th August, 2026 Scrip Code: -531768 Scrip Code: - POLYMED The Manager, The Manager BSE Limited, National Stock Exchange of India Limited Department of Corporate Services, Exchange Plaza, Plot o. C/1-Block-G Phirozee Jeejeebhoy Towers, Bandra Kurla Complex, Bandra(E), Dalal Street, Mumbai-400001. Mumbai-400051. Sub'ect: Submission of Transcri 1-FY26 Earnin Conference Call under the SEBI Listin Obli ation and Disclosure Re uirements Re ulation 2015 Dear Sir/ Madam, Pur uant to Regulation 30(6) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we hereby submit Transcript of the investor Meet/Call held on 10th August 2026, on the Unaudited Financial Results of the Company for the quarter ended 30th June, 2026, on Standalone and Consolidated basis, which were considered and approved by the Board of Director of the Company, at its meeting held on 07th August, 2026. This i for your information and record. Thanking You, Yours Sincerely For Poly Medicure Limited Avinash Chandra Company Secretary M. o. A32270 Encl: As above Plants : Plot No.104-105 & 115-116-117, Sector-~9. HSIIDC Industrial Area, Ballabgarh, Faridabad -121004, Haryana (INDIA) Plot No. 33-34, Sector-68, IMT, Farrdabad-121004, (Haryana) INDIA T: +91-129-4287000, 3355070 “Poly Medicure Limited Q1 FY27 Earnings Conference Call” August 10, 2026 MANAGEMENT: MR. HIMANSHU BAID – MANAGING DIRECTOR – POLY MEDICURE LIMITED MR. RAHUL GAUTAM – PRESIDENT, STRATEGY AND CORPORATE DEVELOPMENT – POLY MEDICURE LIMITED Page 1 of 16 Poly Medicure Limited August 10, 2026 Moderator: Ladies and gentlemen, good day, and welcome to the Poly Medicure Limited Q1 and FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star, then zero on your touch-tone phone. Today on this call, we have with us the senior management team of the company, represented by Mr. Himanshu Baid; the Managing Director, Mr. Rahul Gautam, President, Strategy and Corporate Development. I now hand the conference over to Mr. Himanshu Baid. Thank you, and over to you, sir. Himanshu Baid: Yes. Good evening, everyone, and I welcome you to our Q1 FY27 earnings call. I sincerely thank all of you for being here today. Before I come to numbers, I want to give you a glimpse of our Strategic Vision 2030, and we're calling this as a PolyMed 3.0. As you all know, PolyMed initiated operations in 1997 with an IPO of INR2.65 crores using which we set up our first plant. In the next 25 years, we remained bootstrapped and and slowly built our leadership in our core infusion therapy business by taking building global quality products. During this period, business grew from zero to almost INR7 billion in revenue. In 2021, PolyMed started 2.0 journey, which we call the inflection point in our history of the company. We did our first institutional fundraise, which resulted in multifold expansion of capacity. We also entered into high-technology segments like cardiology, critical care, orthopedics. During this period, we also started our inorganic growth journey with acquisition of PendraCare and Citieffe. Revenue during this period almost went up by 2.75x to INR1,875 crores in FY26. Starting FY27, we have initiated PolyMed 3.0, a phase we are calling Ascent. During this period, we have set a goal to double our revenue by FY30 by unlocking value by organic and inorganic expansion, leveraging technology to scale high complexity verticals globally and deepening direct customer access, especially in international markets. I believe we are at a point of time in our journey where growth should happen exponentially, led by high technology, high-margin segment. Given the strength of our balance sheet where we continue to have strong liquidity, we believe this audacious goal is truly achievable. I'm really excited about this phase, which I believe will truly make PolyMed a global medtech MNC out of India. On the leadership front, we have already initiated actions to achieve our PolyMed 3.0 vision, appointed Indranil Mukherjee as our CEO for India and APAC. Renato Rocha as CEO for Brazil. Indranil has joined the company on 1st June 2026. Renato has joined the company on 1st August 2026. We also brought in Abhimanyu Hooda as Head of Renal business in India to augment sales and also build a strong capability in this segment. I believe our leadership reinforcement will help us to put a strong position to deliver on our aspiration. Page 2 of 16 Poly Medicure Limited August 10, 2026 Moving on to financial performance of the company and Q1 financial results. On the financial performance side, let me start with the stand-alone performance as this remains core for our group. Stand-alone revenue for Q1 was INR431 crores, up 12.3% with domestic at INR146 crores, giving a growth of 16.2% and international at INR281.8 crores, giving a growth of 10%. Gross profit for Q1 was 71.5%, showing significant improvement due to better product mix and impact of price hikes implemented in Q1 and inventory gain. I expect that our gross margin should continue to reflect on historic margin trend of 68% to 69% in the near term. We have guided a stand-alone EBITDA margin of 25% to 27% for FY27, but we have delivered 28%, 100 bps higher than the guided range. Absolute operating EBITDA was INR120.8 crores, up 18.8% on a year-on-year basis. This was despite employee cost rising almost by 29%, driven by 35% increase in minimum wages in Haryana with effect from 1st April 2026, increase in headcount impacting increment for FY27. Now on the consolidated picture, consolidated revenue was INR525 crores, up 30.3%. Of that INR72.3 crores came from acquisitions. So on organic basis, revenue was INR453.1 crores, up 12.4%. Within International, Europe grew 43.8% to INR187.3 crores. And importantly, it grew 17.6% organically, reflecting improvement in the performance in the region. As you know, last year, Europe was a laggard. And this year, as we have added some customers, on-boarded new customers, we were able to come back to our original growth or planned growth of 17% to 18% as we had forecasted in the beginning of the year. Rest of the World grew at 30.3% on a reported basis, but only 4.0% organically. The reason for low growth was 32% de-growth in the Middle East due to ongoing West Asia crisis. Customer demand in the region is intact, but given the current logistics and infrastructure bottlenecks, we are unable to meet that demand. We are hopeful that once the situation improves in the region, we will return to normalcy. Our order book is pretty strong for Middle East, but currently, we are unable to ship the products. Consolidated gross profit was INR385.6 crores at a margin of 73.4% margin, up 495 basis points. The better margin profile of the newly acquired business is helping improve gross margin. Consolidated operating EBITDA was INR126.7 crores, up 17.7% at a margin of 24.1% with our guided range -- within our guided range of 23% to 25% for the year. Infusion Therapy grew by 11.1% to INR259.2 crores, led by strong domestic growth on back of rising share of higher value-added products and price increases. Internationally, we have started to witness a strong recovery in the business despite 32% degrowth in the Middle Eastern markets. Orthopedic contributed INR49.2 crores, which reflects the consolidation of Citieffe. Cardiology grew from INR2.9 crores to INR28.6 crores led by PendraCare acquisition together with genuine scale up of domestic business. Others grew by 18.5% to INR141.9 crores constituting the balance. The one [Showing first 8,000 characters — download PDF for full document]